Entheon Biomedical Income Statement

Financials in millions CAD. Fiscal year is December - November.

Millions CAD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	May '24 May 31, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021	Nov '20 Nov 30, 2020	Nov '19 Nov 30, 2019
Revenue	-	0.25	0.19	-	-	-
Revenue Growth (YoY)	-	31.97%	-	-	-	-
Gross Profit	-	0.25	0.19	-	-	-
Selling, General & Admin	0.36	0.56	2.5	4.45	1.2	0.53
Research & Development	-	-	1.2	1.21	0.44	0.13
Operating Expenses	0.35	0.56	3.79	8.21	1.64	0.66
Operating Income	-0.35	-0.31	-3.6	-8.21	-1.64	-0.66
Interest & Investment Income	0.02	0.01	0	0.01	0.01	-
Currency Exchange Gain (Loss)	-0	-0	0.02	0	-	-
Other Non Operating Income (Expenses)	0	0	0.25	-0	-2.74	-0.01
EBT Excluding Unusual Items	-0.33	-0.3	-3.33	-8.2	-4.38	-0.67
Gain (Loss) on Sale of Investments	-0	0	-0.07	0.21	0.05	-
Gain (Loss) on Sale of Assets	-	-	1.34	-	-	-
Other Unusual Items	-	-	-	-	-0.05	-
Pretax Income	-0.34	-0.3	-2.06	-8	-4.38	-0.67
Earnings From Continuing Operations	-0.34	-0.3	-2.06	-8	-4.38	-0.67
Earnings From Discontinued Operations	-	-	-6.46	-0.89	-	-
Net Income	-0.34	-0.3	-8.52	-8.89	-4.38	-0.67
Net Income to Common	-0.34	-0.3	-8.52	-8.89	-4.38	-0.67
Shares Outstanding (Basic)	6	6	6	5	3	0
Shares Outstanding (Diluted)	6	6	6	5	3	0
Shares Change (YoY)	6.00%	-	8.85%	97.83%	543.78%	-
EPS (Basic)	-0.05	-0.05	-1.44	-1.64	-1.60	-1.57
EPS (Diluted)	-0.05	-0.05	-1.44	-1.64	-1.60	-1.57
Free Cash Flow	-0.35	-0.36	-1.95	-5.33	-2.85	-0.47
Free Cash Flow Per Share	-0.06	-0.06	-0.33	-0.98	-1.04	-1.11
Gross Margin	-	100.00%	100.00%	-	-	-
Operating Margin	-	-125.43%	-1898.18%	-	-	-
Profit Margin	-	-119.85%	-4492.23%	-	-	-
Free Cash Flow Margin	-	-143.79%	-1030.49%	-	-	-
EBITDA	-	-	-3.6	-8.18	-1.64	-
D&A For EBITDA	-	-	0	0.04	0	-
EBIT	-0.35	-0.31	-3.6	-8.21	-1.64	-0.66
EBIT Margin	-	-125.43%	-	-	-	-
Revenue as Reported	-	0.25	0.19	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.